Paraoxonase 1 mutations in a Turkish population

被引:39
作者
Aynacioglu, AS [1 ]
Cascorbi, I
Mrozikiewicz, PM
Nacak, M
Tapanyigit, EE
Roots, I
机构
[1] Humboldt Univ, Univ Clin Charite, Inst Clin Pharmacol, Berlin, Germany
[2] Gaziantep Univ, Fac Med, Dept Pharmacol, Gaziantep, Turkey
关键词
paraoxonase; polymorphism; molecular epidemiology; Turkish population;
D O I
10.1006/taap.1999.8690
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human serum paraoxonase 1 (PON1) catalyzes the hydrolysis of certain organophosphate pesticides and nerve gases and so may alter significantly an individual's susceptibility to the toxicity of these chemicals. Moreover, PON1 hydrolyzes lipid peroxides complexed to low density lipoproteins (LDL) and therefore it was suggested that PON1 may be one of the genes that is involved in the pathogenesis of cardiovascular diseases. Its activity shows interindividual and interethnic variability. At least two mutation sites, namely Gln192Arg (Q/R) and Leu55Met (L/M) were reported responsible for the variations in enzyme activity. The aim of the present study was to determine the frequency of these mutations in Turks and compare the results with other European and Oriental populations. A total of 381 unrelated Turkish individuals were genotyped for Gln192Arg and Leu55Met polymorphisms by PCR-RFLP using AlwI and NlaIII, respectively. Genotype distribution was QQ = 0.49, QR = 0.40, RR = 0.11, and LL = 0.52, LM = 0.39, MM = 0.09. Thus frequencies of high activity alleles R (Arg) and L (Leu) were found as 0.31 and 0.72, respectively. The frequency of these alleles was slightly higher in Turkish subjects than other Caucasian populations but much lower compared to Oriental populations, (C) 1999 Academic Press.
引用
收藏
页码:174 / 177
页数:4
相关论文
共 21 条
  • [1] ADKINS S, 1993, AM J HUM GENET, V52, P598
  • [2] The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
    Antikainen, M
    Murtomaki, S
    Syvanne, M
    Pahlman, R
    Tahvanainen, E
    Jauhiainen, M
    Frick, MH
    Ehnholm, C
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) : 883 - 885
  • [3] Aynacioglu AS, 1998, ARCH TOXICOL, V72, P215
  • [4] Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population
    Aynacioglu, AS
    Cascorbi, I
    Mrozikiewicz, PM
    Roots, I
    [J]. PHARMACOGENETICS, 1997, 7 (04): : 327 - 331
  • [5] Blatter Garin Marie-Claude, 1997, Journal of Clinical Investigation, V99, P62
  • [6] CASCORBI I, 1995, AM J HUM GENET, V57, P581
  • [7] CASCORBI I, 1999, IN PRESS PHARMACOGEN
  • [8] The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study
    Herrmann, SM
    Blanc, H
    Poirier, O
    Arveiler, D
    Luc, G
    Evans, A
    MarquesVidal, P
    Bard, JM
    Cambien, F
    [J]. ATHEROSCLEROSIS, 1996, 126 (02) : 299 - 303
  • [9] THE MOLECULAR-BASIS OF THE HUMAN SERUM PARAOXONASE ACTIVITY POLYMORPHISM
    HUMBERT, R
    ADLER, DA
    DISTECHE, CM
    HASSETT, C
    OMIECINSKI, CJ
    FURLONG, CE
    [J]. NATURE GENETICS, 1993, 3 (01) : 73 - 76
  • [10] ANALYSIS OF THE SERUM PARAOXONASE ARYLESTERASE POLYMORPHISM IN A TURKISH POPULATION
    KARAKAYA, A
    SUZEN, S
    SARDAS, S
    KARAKAYA, AE
    VURAL, N
    [J]. PHARMACOGENETICS, 1991, 1 (01): : 58 - 61